Barrett's Metaplasia Mutational Load for Progression Risk Stratification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for managing Barrett's metaplasia (BM) are challenged by subjective microscopic classification and the need to differentiate between stable and progressive disease, lacking objective risk assessment for progression to esophageal adenocarcinoma (EA).

Innovation Solution

A method involving DNA sequencing and analysis of microsatellite regions to determine mutational load, categorizing clonality of mutations, and assigning risk categories based on pre-determined cut-offs to predict disease progression, enabling targeted surveillance or treatment modalities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If subjective microscopic classification is used to manage Barrett's metaplasia, then diagnostic simplicity is maintained, but measurement precision and reliability of disease progression assessment deteriorate

Engineering Contradiction:

Improvediagnostic simplicityVSAvoiddisease progression assessment precision

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent replaces subjective microscopic classification (mechanical/visual inspection) with molecular genetic analysis (DNA sequencing and mutational load calculation). This substitution transforms the diagnostic approach from qualitative visual assessment to quantitative molecular measurement, thereby improving measurement precision while maintaining operational feasibility through standardized genetic testing protocols

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the diagnostic parameter from morphological features observed under microscope to molecular genetic parameters (mutational load, clonality metrics). By measuring DNA mutations and clonality in Barrett's epithelium, the system achieves more precise and objective assessment of disease progression risk, replacing subjective histological grading with quantifiable genetic markers

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If uniform surveillance is applied to all Barrett's metaplasia patients, then management simplicity is maintained, but loss of information regarding individual patient risk stratification increases

Engineering Contradiction:

Improvemanagement simplicityVSAvoidindividual patient risk information

Core Design Contradiction:

Ease of operationVSLoss of information

Solution Approach 1:

The patent applies local quality by stratifying patients into different risk categories (low, intermediate, high) based on their individual mutational load and clonality profiles. Instead of uniform management, each patient receives tailored surveillance or treatment recommendations appropriate to their specific molecular risk characteristics, preserving individual risk information while maintaining systematic management through category-based protocols

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the Barrett's metaplasia patient population into distinct risk groups based on molecular genetic analysis. By dividing patients into low-risk (surveillance can be discontinued), intermediate-risk (standard surveillance), and high-risk (intervention recommended) categories, the system prevents loss of individual risk information while enabling simplified category-specific management strategies

Inventive Principle:

Principle #1Segmentation

3Reliability

If early intervention is implemented for all Barrett's metaplasia cases, then disease progression prevention is improved, but use of energy and treatment-related harm increase

Engineering Contradiction:

Improvedisease progression preventionVSAvoidtreatment-related harm

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial action by recommending intervention only for high-risk patients identified through molecular risk stratification, rather than universal intervention. Low-risk patients receive no intervention (surveillance discontinuation), intermediate-risk patients receive standard surveillance, and only high-risk patients with high mutational load and clonality receive treatment. This selective approach maintains disease progression prevention for those who need it while minimizing treatment-related harm by avoiding unnecessary interventions in low-risk individuals

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Provides an objective risk assessment for disease progression from BM to EA, allowing for personalized management strategies such as monitoring or intervention, reducing variability and improving early intervention.

Implementation Method 1

amplifying DNA sequences from a biological specimen from the subject

Methodology Applied

Scientific EffectPolymerase chain reaction:

Implementation Method 2

detecting mutations in microsatellite regions of the amplified DNA sequences

Methodology Applied

Scientific EffectDNA sequencing:

Data Source

PatentUS20250349390A1Methods for treating barrett's metaplasia and esophageal adenocarcinoma

Publication Date: 2025.11.13 INTERPACE DIAGNOSTICS CORPORATION

AI summary

Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.